| Autor: |
Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Veronica Candi, Ludovica Pengue, Maria Livia Del Giudice, Irene Attucci, Francesca Bacchiarri, Ubaldo Occhini, Maria Teresa Pirrotta, Federico Perfetto, Monica Bocchia, Alessandro Gozzetti |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Personalized Medicine. 12:484 |
| ISSN: |
2075-4426 |
| DOI: |
10.3390/jpm12030484 |
| Popis: |
Systemic amyloidosis arises from monoclonal CD38+ plasma cells that produce misfolded immunoglobulin light chains, which form amyloid fibrils that are deposited into different tissues, leading to organ damage. Daratumumab is a human IgG/k monoclonal antibody that targets CD38, a glycoprotein uniformly expressed on human plasma cells. Daratumumab has been utilized in recent years with unprecedented responses in multiple myeloma. In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and improvement in organ function. Here, we report real-life treatment with Daratumumab in 33 AL amyloidosis patients treated within the Regional Tuscan Myeloma network at 5 centers with associated MGUS or SMM (n = 15) or symptomatic MM (n = 18). Patients were treated at relapsed/refractory disease stages (n = 29) with a median of one previous line of therapy or at diagnosis (n = 4). Daratumumab showed good efficacy, representing 60% of good hematological responses and 50% of organ responses in a real-life population of patients with an acceptable toxicity profile. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
